Chemotherapy-induced neutropenia, including febrile neutropenia (FN), is a major dose-limiting toxicity of many common systemic chemotherapy regimens, and is associated with substantial morbidity, mortality, and cost. [1] [2] [3] [4] Neutropenic complications also can cause treatment delays and may result in reduced delivered chemotherapy dose intensity, potentially compromising disease control and long-term survival in patients treated with curative intent. 5, 6 Myeloid growth factors (MGFs) have been shown to reduce the incidence, duration, and severity of neutropenic events across a broad range of malignancies and regimens, often enabling the delivery of full chemotherapy dose intensity. 7, 8 A number of randomized, controlled trials confirming the impact of MGFs on reducing the risk of FN have been published over the past few years. [9] [10] [11] [12] [13] Significant reductions in the risk of FN were observed in both non-Hodgkins lymphoma and solid tumor studies, in studies featuring all adult age groups, and with all forms of granulocyte colony-stimulating factor (G-CSF). In addition to confirming a reduction in the relative risk of FN, this analysis showed a significant reduction in infection-related mortality.
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The decision to use primary CSF prophylaxis for patients undergoing chemotherapy is generally based on clinical judgment, including (1) the estimated risk of neutropenic complications expected based on the treatment regimen; (2) patient-specific characteristics including age, functional status, and comorbidities; and (3) treatment intention, balancing the anticipated benefit of chemotherapy with the risk of serious and lifethreatening complications. 14 A risk model for first-cycle severe neutropenia or FN is under development, based on a prospective registry of nearly 4500 patients treated with a chemotherapy regimen at 117 randomly selected practices in the United States. 15 Independent risk factors in multivariate analysis included the type of cancer, treatment regimen, age, certain comorbidities (liver disease, renal disease, diabetes) and concomitant medications, baseline blood counts, the intention to provide full-dose chemotherapy, and no prophylactic CSF support. Once fully validated, such a risk model may guide clinicians and patients on the most efficacious and cost-effective use of MGFs.When compelling clinical indications for the use of MGFs do not exist based on reducing the risk of FN or infection-related mortality, the decision to use these agents may be based on economic considerations. [16] [17] [18] Clinical practice guidelines are generally based on systematic review and are designed to guide practitioners and patients in making informed decisions about appropriate health care. This article summarizes and contrasts recently developed or updated guidelines for the use of MGFs. The results of recently conducted, randomized controlled trials and metaanalyses of these trials were reviewed by the respective guidelines panels. The similarities and differences between the guidelines content and process are summarized and contrasted.
Methods
Three sets of clinical practice guidelines for the use of MGFs have been developed or updated recently by major professional oncology organizations: the American Society of Clinical Oncology (ASCO), the National Comprehensive Cancer Network (NCCN), and the European Organization for Research and Treatment of Cancer (EORTC). ASCO published their initial clinical practice guidelines for the use of the hematopoietic CSFs in 1994. 19 These guidelines were subsequently updated in 1996, 1997, and 2000, and ASCO completed the most recent update in 2006 with the most extensive revision since the original report. 20, 21 In 2005, the NCCN presented and published initial guidelines on the use of MGFs. These were updated in 2006 and 2007 (in this issue) as part of a systematic annual update. 22, 23 In 2006, the EORTC published guidelines for the use of the CSFs in adults with lymphoma and solid tumors. 24 The EORTC guidelines were intended to complement previously published guidelines on the use of the CSFs in the elderly. 25 The authors undertook a comprehensive review and comparison of these 3 guidelines using a priori structured content criteria and previously validated quality appraisal tools. Content areas extracted for each guideline included recommendations related to primary prophylaxis, secondary prophylaxis, therapeutic use, afebrile neutropenia, sustaining dose intensity, progenitor cell transplant, acute leukemia and myelodysplasia, older patients, pediatric patients, schedule and dose, granulocyte-versus granulocytemacrophage-CSF, and radiation injury. In addition, risk factors associated with disease, treatment, and patient-specific factors such as age, gender, ethnicity, performance status, and the presence of comorbidities or laboratory abnormalities were considered. Guideline content was also contrasted for the major chemotherapy regimens and assumed rates of FN associated with each regimen.
The quality of the recently updated or developed guidelines was then critically appraised using the Appraisal of Guidelines Research and Evaluation (AGREE) instrument, which provides a framework for assessing the quality of clinical practice guidelines based on the potential for bias in guideline development as well as the internal and external validity and feasibility for practice. 26 The AGREE instrument was developed using a sequential process that included item generation, selection, scaling, field evaluation, and finalization. An initial list of 82 items was extracted from existing tools and relevant literature addressing these domains. 27 The internal consistency of the final
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Original Article 21 The flow sheet assesses the justification for using a leukocyte growth factor for primary or secondary prevention, therapy, or other reasons and then provides a framework for documenting dose, schedule, and actual administration of such support. Primary prophylaxis is recommended routinely for a risk of FN of 20% or more but not for patients at a less than 10% risk. Patients with a risk of 10% to 20% should be assessed for individual risk based on disease-, treatment-, and patient-specific factors.
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instrument was acceptable, with Cronbach's alpha ranging from 0.64 to 0.88 and intra-class correlation coefficients ranging from 0.57 to 0.91 with different appraisers.
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The use of the AGREE instrument involves consideration of the benefits, possible harm, and costs of the recommendations as well as their practical use. Therefore, the assessment includes judgments about the methods used for developing the guidelines, the content of the final recommendations, and the factors linked to their application. The AGREE instrument assesses both the quality of the recommendations and reporting.
The tool consists of 23 key items organized in 6 domains, each intended to capture a separate dimension of quality. Items 1 to 3 assess the scope and purpose of guideline, the clinical questions being asked, and the target population. Items 4 through 7 reflect the stakeholder involvement or the extent to which the guideline represents the views of its users. Items 8 to 14 assess the rigor of guideline development or the process used to gather and synthesize the evidence, and the methods of developing the recommendations and updating them. Items 15 to 18 evaluate the clarity and presentation of the guidelines in terms of language and format. Items 19 to 21 assess the applicability of the guidelines, including the impact on behavior and costs. Items 22 and 23 evaluate the editorial independence of the recommendations and any conflicts of interest.
As recommended by the developers, the guidelines were assessed by 2 independent appraisers (GHL, JMK). Each scale item was rated from 4, "Strongly Agree," to 1, "Strongly Disagree," with 3, "Agree," and 2, "Disagree." Domain scores were calculated by summing up all the scores of the individual scale items in a domain. The total score was standardized by presenting the score as a percentage of the maximum possible score for each domain. The developers recommend that the domain scores not be aggregated into a single score and that they be presented and compared independently.
Results
The MGF guidelines from the NCCN were initially developed in 2005 and updated in 2006 and 2007. As summarized in Figure 1 , these guidelines recommend a stepwise process, starting with an initial evaluation based on type of cancer, chemotherapy regimen, patient-specific risk factors, and treatment intention. This is to be followed by a formal risk assessment and a recommendation on the use of MGFs based on the level of risk. Unlike the ASCO guidelines in effect at the time, the NCCN guidelines recommended use of G-CSF prophylaxis when patients are thought to be at 20% or greater risk. Patients at intermediate risk (10%-20%) may be considered for prophylactic G-CSF if additional considerations place the patient at greater risk for FN or for serious consequences of FN such as prolonged hospitalization or death. Routine prophylaxis with G-CSF should not be employed in patients thought to have a low risk of FN (under 10%).
The 2006 ASCO White Blood Cell Growth Factor Guidelines Update Committee agreed unanimously that reduction in FN was an important clinical outcome that justified use of the CSFs when the risk of FN was about 20% and no other equally effective regimen that did not require CSF was available. This was a distinct change from the threshold recommended in previous ASCO guidelines for approximately 12 years. An additional change with the 2006 guidelines was the introduction of several derivative products such as executive and patient summaries, a
Comparison of Myeloid Growth Factor Guidelines PowerPoint slide set, and a work sheet or flow chart to assist practitioners in applying the guidelines and monitoring for compliance when appropriate. As shown in Figure 2 , this flow sheet assessed justification for using CSFs and the treatment plan, including dose, schedule, route, and duration of use of the leukocyte growth factors. The EORTC also issued guidelines for the use of G-CSF in 2006. As shown in Figure 3 , the overall recommendation for prophylactic use of G-CSF is remarkably similar to that of the NCCN and revised ASCO guidelines, with routine use for patients undergoing a chemotherapy regimen with a 20% or greater risk, none when the risk is less than 10%, and individual risk assessment for patients receiving a regimen associated with a risk of 10% to 20%. If the individual patient risk for FN after such assessment is deemed to be 20% or greater, primary prophylaxis with G-CSF is recommended. Table 1 summarizes and compares recommendations of the 3 MGF guidelines for the major topics discussed in the Methods section. Clearly, not every topic was discussed or equally considered across all guidelines. However, remarkable similarity in the final recommendations is observed for the 3 guidelines for primary prophylaxis, secondary prophylaxis, sustaining dose intensity, and treating elderly patients. The guidelines are consistent in recommending consideration of prophylactic CSFs when the risk of FN is 20% or greater (Table  2) . Likewise, the recommendations are consistent that patients at lower levels of risk should have individual risk assessed by the clinician, with CSF use considered if enough risk factors such as advanced age are present to indicate a greater level of individual patient risk than the randomized controlled trials for a given regimen might otherwise indicate. phosphatase; low hg; preexisting Hb <12 g/dL; Serum albumin ANC < 1000 or lymphocytopenia < 3.5 g/dL; Pretreatment ANC <1500 Abbreviations: FN, febrile neutropenia; XRT, x-ray therapy; G-CSF, granulocyte colony-stimulating factor; LDH, lactate dehydrogenase; ECOG, Eastern Cooperative Oncology Group; COPD, chronic obstructive pulmonary disease; ANC, absolute neutrophil count; *Indiscriminant use of antibiotic prophylaxis is not recommended. Table 3 summarizes and contrasts the disease-, treatment-, and patient-related factors believed to increase the risk of FN and its complications in each guideline. Although some differences in emphasis exist, the guidelines are consistent in recognizing the importance of assessing patient-specific risk factors such as advanced disease, previous episodes of FN, prior extensive chemotherapy, age 65 years or greater, poor performance or nutritional status, serious comorbidities, and low baseline blood counts or bone marrow involvement. Issues related to the use of the CSFs for treating FN, afebrile neutropenia, progenitor cell transplantation, acute leukemia and myelodysplastic syndromes, and pediatric patients, and the recommended dose and schedule are not addressed by all of the guidelines ( Table 1) .
Comparison of Myeloid Growth Factor Guidelines
Each of the guidelines lists common regimens associated with varying levels of risk for FN. Table 4 summarizes and compares regimens considered representative of those used to treat common cancers and the assumed level of risk for FN associated with these regimens. Given the differences in process and the inherent variation in oncology practice between Europe and the United States, differences in the regimens mentioned are not a surprise. The EORTC guidelines present considerably more regimens, including many not mentioned in the ASCO and NCCN guidelines. Although the presumed risk of FN with different regimens is relatively comparable across guidelines, differences in how clinical trial data on the risk of FN with common regimens are interpreted are shown in these guidelines, including doxorubicin and cyclophosphamide (AC) and AC-docetaxel in breast cancer and cisplatinum and paclitaxel (DP) in lung cancer.
Finally, each guideline was critically appraised by the authors independently using the previously validated AGREE instrument, with discrepancies resolved as discussed in Methods. Table 5 summarizes and contrasts the results of this critical appraisal by domain of focus of the scale. For issues related to the scope and purpose, stakeholder involvement, and guidelines applicability, little or no differences in appraisal were found.
The NCCN guidelines were appraised as less rigorous in development, largely because of the consensus process employed as compared with a more rigorous evidence-based approach used by ASCO and EORTC. Although a literature review was undertaken by each of the panels, the review process was found to be more systematic and comprehensive in the ASCO and EORTC guidelines, because no criteria for the search and selection of relevant literature are presented in the NCCN guidelines. Differences are also noted in the review process, with an explicit process for independent and external review of the ASCO and EORTC guidelines. Similarly, no individual conflicts of interest are listed for panel members of the NCCN panel but these are listed for the ASCO and EORTC guidelines. In contrast, the NCCN guidelines are updated annually, but no explicit process is stated for updating the ASCO and EORTC guidelines. In addition, clarity
Comparison of Myeloid Growth Factor Guidelines Abbreviations: CSFs, colony-stimulating factors; FN, febrile neutropenia; QOL, quality of life. *The numbers associated with each scale represent ratings from 1 (strongly disagree); 2 (disagree); 3 (agree); to 4 (strongly agree).
of presentation favors the NCCN guidelines, with recommendations generally presented in both text and algorithmic diagrams for ease of access and use. Although no meaningful overall summary measure can be derived from the critical appraisal, the differences observed are largely accounted for by the differences in process used by the groups involved. All guidelines also recommend further clinical investigation of a number of areas that remain unclear.
Discussion
Chemotherapy-induced neutropenia and its complications are major dose-limiting toxicities of cancer chemotherapy, and MGFs have been shown to reduce the risk of FN and its related complications. Three different practice guidelines were recently published by major professional organizations. Comprehensive review and comparison of these guidelines show remarkable consistency in recommending use of CSF primary prophylaxis in patients at approximately a 20% risk of FN or greater. All guidelines also recommend considering CSF use for patients determined to be at increased risk after risk assessment by the clinician. The quality of clinical practice guidelines have recently been brought into question. 29 Overall, quality of the MGF guidelines was rated as good, with little or no difference between guidelines in the stated scope and purpose, stakeholder involvement, and applicability. Although more emphasis on systematic and comprehensive literature reviews is seen in the ASCO and EORTC guidelines process, the NCCN guidelines are updated on an annual basis and appear to offer better clarity of presentation.
